Nereus Pharmaceuticals received $18.3 million in a second tranche of its fourth round of venture capital. The tranche was triggered by the company's success at hitting milestones in its drug development work. The FDA has cleared two INDs for Nereus' oncology drug candidates.
- here's the release for more information